Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00352105 · OUTCOME

Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity

Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer · Source last updated 2012-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
at 1 year after start of treatment

What was measured

Any toxicity greater than or equal to Grade 1= mild

Groups in this outcome

5-FU, Cisplatin, Radiation and Iressa

Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
5-FU, Cisplatin, Radiation and Iressa60

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-FU, Cisplatin, Radiation and Iressa60Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        60
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    units
    Participants
description
Any toxicity greater than or equal to Grade 1= mild
groups
  1. description
    Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    5-FU, Cisplatin, Radiation and Iressa
param Type
NUMBER
reporting Status
POSTED
time Frame
at 1 year after start of treatment
title
Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice